# Retatrutide versus Ozempic: trial data Canonical: https://europeanpeptideshop.com/blog/retatrutide-vs-ozempic-transcend-t2d-2/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Lilly reported new Phase 3 results on October 28, 2026 from TRANSCEND-T2D-2, comparing investigational retatrutide with Ozempic 2 mg in adults with type 2 diabetes. This is a direct comparison within one trial, which makes it more informative for that specific question than lining up percentages from unrelated studies. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) ## What question did the trial ask? The ClinicalTrials.gov record describes a randomized, open-label, parallel-group study in adults whose diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. Its primary outcome is change in HbA1c at week 80; body-weight changes are listed among the secondary outcomes. [2](https://clinicaltrials.gov/study/NCT06260722) That design identifies the population and comparison being tested. It does not automatically answer the same question in people without diabetes, with another semaglutide formulation or at a different follow-up time. ## What did Lilly report? Lilly's efficacy-estimand analysis reported the following average changes at 80 weeks. The company described detailed presentation and peer-reviewed publication as forthcoming in its announcement. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) Outcome | Retatrutide 9 mg study arm | Retatrutide 12 mg study arm | Ozempic 2 mg comparator Body-weight change | −19.5% | −20.9% | −9.4% HbA1c change | −2.2 percentage points | −2.2 percentage points | −1.8 percentage points Discontinued because of adverse events | 4.8% | 7.9% | 2.7% [1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) ## Why do the analysis details matter? An efficacy estimand asks about an outcome under specified treatment-adherence assumptions. It should be read with its definition, not treated as a prediction for every person who might begin a treatment. Lilly specifies that this analysis assumes participants remained on study intervention without certain additional glucose-lowering medication. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) A practical reading method is to keep the endpoint, study population, time point and analysis approach next to every percentage. If one of those changes, the comparison changes too. The table describes trial arms; it is not a dosing guide. ## Why are the registry and announcement numbers different? The registry record available at this check, last posted September 28, retains estimated enrollment of 1,250 and an active-not-recruiting status. Lilly's later announcement describes 1,298 participants. These are differently dated records, so the older registry estimate should not silently replace the sponsor's reported enrollment. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) [2](https://clinicaltrials.gov/study/NCT06260722) The registry also distinguishes primary completion from overall study completion. That distinction helps explain how a main outcome can be announced while longer follow-up remains relevant. [2](https://clinicaltrials.gov/study/NCT06260722) ## What does this change about approval status? Lilly's current retatrutide information still describes it as investigational and not an approved medicine. Trial results, regulatory submission and approval are separate milestones. [3](https://www.lilly.com/news/stories/what-to-know-about-retatrutide) For ongoing reading, use the named trial report for its specific outcome and the broader comparison guide for receptor targets and differences between studies. Neither a clinical-trial result nor a shared ingredient name validates a research catalogue vial. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Lilly: TRANSCEND-T2D-2 topline results, October 28, 2026](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) - [ClinicalTrials.gov: NCT06260722](https://clinicaltrials.gov/study/NCT06260722) - [Lilly: What to know about retatrutide](https://www.lilly.com/news/stories/what-to-know-about-retatrutide) ## More articles Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026 Research news · 3 min read ## [CT-G32 versus retatrutide](https://europeanpeptideshop.com/blog/ct-g32-sco-940-four-pathway-peptide/) Explore CT-G32/SCO-940’s four-pathway design, the reported rat comparison with retatrutide and what a planned US FDA IND does: and does not: mean. 8 November 2026 Research news · 3 min read ## [Eloralintide and the EloraTZP trial](https://europeanpeptideshop.com/blog/eloralintide-tirzepatide-eloratzp-trial/) Understand Lilly's eloralintide and tirzepatide EloraTZP Phase 2b study, the population tested, combination results, tolerability and development stage. 8 November 2026